<?xml version="1.0" encoding="utf-8"?> 

<rss version="2.0"> 

<channel>

<title>LexisNexis&#174; Mealey's&#8482; Emerging Drugs &amp; Devices Legal News</title>

<link>http://www.lexisnexis.com/mealeys/news.aspx</link>

<description>Headline Emerging Drugs &amp; Devices Legal News from LexisNexis&#174;</description>

<language>en-us</language>

<image>

<title>LexisNexis&#174; Headline Emerging Drugs &amp; Devices Legal News</title>

<url>http://www.lexisnexis.com/mealeys/images/lexismealeyslogo.gif</url>

<width>130</width> 
  
<height>29</height>

<link>http://www.lexisnexis.com/mealeys/news.aspx</link>

</image> 

<copyright>Copyright 2009</copyright>

<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Generic Drug Injury Claims Are Not Preempted, 8th Circuit Panel Rules</title>
<description>
<![CDATA[ST. LOUIS - Federal law does not preempt state court failure-to-warn claims against generic drug manufacturers, a panel of the Eighth Circuit U.S. Court of Appeals ruled Nov. 27, extending the U.S. Supreme Court's preemption ruling in Wyeth v. Diana Levine (No. 06-1249, U.S. Sup.; 2009 U.S. LEXIS 1774; See 3/5/09, Page 5) to generic drugs (Gladys Mensing v. Wyeth, Inc., et al., No. 08-3850, 8th Cir.; 2009 U.S. App. LEXIS 25911; See 10:15/09, Page 8). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Federal Trial Court: Levine Doesn't Apply To Generic Drugs</title>
<description>
<![CDATA[SAN JOSE - The U.S. Supreme Court's drug preemption ruling in Wyeth v. Diana Levine (No. 06-1249, U.S. Sup.; 2009 U.S. LEXIS 1774; See 3/5/09, Page 5) does not discuss applicability to generic drugs and does not change a 2008 preemption ruling, a California federal judge ruled Nov. 24 (Margarita Gaeta, et al. v. Perrigo Pharmaceuticals Co., et al., No. 05-4115, N.D. Calif., San Jose Div.; See 6/19/08, Page 6). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Reglan Makers Off Hook; Only Manufacturer Is Liable Under Louisiana State Law</title>
<description>
<![CDATA[MONROE, La. - Though it results in an inequity to a patient allegedly injured by the heartburn drug metoclopramide, a Louisiana federal judge on Nov. 23 ruled that the state's product liability law bars claims against two brand-name drug manufactures who did not make the generic drug that the plaintiff took (Penny Morris, et al. v. Wyeth, Inc., et al., No. 09-854, W.D. La., Monroe Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Zyprexa MDL Judge Hands Miss. 1st Setback In States' Medicaid Litigation</title>
<description>
<![CDATA[BROOKLYN, NY - Mississippi became the first of more than 40 states to suffer a setback in state government Zyprexa litigation on Dec. 1 when the judge overseeing the Zyprexa multidistrict litigation granted summary judgment on most of Mississippi's claims and expressed doubts about the viability of the one that survived (In Re: Zyprexa Products Liability Litigation, MDL Docket No. 1596, No. 04-md-1596, Jim Hood, et al. v. Eli Lilly &amp; Company, No. 07-645, E.D. N.Y.; See 7/27/06, Page 6). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Aredia / Zometa Plaintiffs Fail To Surmount Michigan Drug Shield Law</title>
<description>
<![CDATA[CINCINNATI - Michigan's drug preemption law bars the claims of three plaintiffs who claim they were injured by two Novartis bone-loss prevention drugs, a federal appeals court ruled Nov. 24 in affirming summary judgment (In Re: Aredia and Zometa Products Liability Litigation, Patricia Fragomeli, et al. v. Novartis Pharmaceuticals Corporation, Nos. 08-5573, 08-5574 and 08-5575, 6th Cir.; See 3/5/09, Page 21). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>2nd Fosamax Bellwether Case Dismissed When Doctors Are Disqualified As Experts</title>
<description>
<![CDATA[NEW YORK - The second of three bellwether trials scheduled in the federal Fosamax multidistrict litigation was dismissed on summary judgment on Nov. 23 after the judge found that two treating physicians were not qualified to testify as causation experts (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 06-md-1789, Bessie Flemings v. Merck &amp; Co., Inc., No. 06-7631, S.D. N.Y.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>N.J. Punitives Law Applied To Aredia / Zometa Cases</title>
<description>
<![CDATA[NEW BRUNSWICK, N.J. - The judge overseeing New Jersey's Aredia/Zometa litigation on Nov. 23 decided to apply New Jersey's limited punitive damage law in two cases brought by out-of-state plaintiffs (In Re: Aredia and Zometa, No. 278, Walter Bagley v. Novartis Pharmaceuticals Corp., No. L-6027-08MT, and Beverly Meng v. Novartis Pharmaceuticals Corp., No. L-7670-07MT, N.J. Super., Middlesex Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>2 Breast Cancer Patients Awarded $103 Million In In Punitive Damages</title>
<description>
<![CDATA[PHILADELPHIA - An Illinois woman who was awarded $6.3 million in compensatory damages on Nov. 20 by a Pennsylvania state court jury that found her use of hormone replacement therapy was a contributing cause of her breast cancer will receive an additional $28 million in punitive damages, the jury decided Nov. 23, while Wyeth, the manufacturer of one of the drugs, was ordered to pay $75 million to another Illinois woman, whose trial over similar injuries ended in late October (Donna Kendall v. Wyeth Pharmaceuticals Inc., et al., No. 040600965; Connie Barton v. Wyeth Pharmaceuticals Inc., et al., No. 040406301, Pa. Comm. Pls., Philadelphia Co.; See 11/2/09, Page 9). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Recall Doesn't Prevent Federal Preemption In Thermal Ablation Case</title>
<description>
<![CDATA[HATTIESBURG, Miss. - The recall of a thermal ablation device does not save from preemption the claims of a plaintiff who says she was burned when the device allegedly malfunctioned, a Mississippi federal judge ruled Nov. 12 (Jan Hughes v. Boston Scientific Corporation, No. 08-79, S.D. Miss., Hattiesburg Div.; See 3/5/09, Page 19). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Res Ipsa Loquitor Claim In Hip Implant Case Doesn't Parallel FDA Control</title>
<description>
<![CDATA[HOUSTON - A Texas federal judge on Dec. 1 said a man's claim involving an allegedly contaminated Trident hip implant is preempted and the claim does not parallel federal regulations (Ronald Funk v. Stryker Corporation, No. 09-733, S.D. Texas, Houston Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 11%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Wrongful Death Claims Stemming From Remicade Use Dismissed For Lack Of Proof</title>
<description>
<![CDATA[BALTIMORE - The parents of a 17-year-old who died of cardiac arrest after several infusions with Johnson &amp; Johnson's Remicade saw their claims dismissed for failure to provide an expert to show that the drug was defective, a federal judge ruled Nov. 24 (James Mack, et al. v. AmerisourceBergen Drug Corporation, et al., No. 08-688, D. Md.; 2009 U.S. Dist. LEXIS 109705). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 11 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 12%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>N.J. Accutane Judge To Allow New Science Expert In Upcoming IBD Retrial</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - In the wake of new scientific evidence, a New Jersey state court judge on Nov. 18 reversed herself and allowed parties in an Accutane retrial to designate new or substitute science and/or causation experts (In Re: Accutane Litigation, No. 271 MT, N.J. Super., Atlantic Co.; See 9/17/09, Page 16). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 12 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 13%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$17.5M Of Propulsid Funds Go To Canadian Settlement, Charitable Fund</title>
<description>
<![CDATA[NEW ORLEANS - The judge overseeing the Propulsid multidistrict litigation on Nov. 30 ordered that $17.5 million of the $77.6 million first settlement program be used to fund a recently approved Canadian settlement involving the same drug and to a charity fund (In Re: Propulsid Products Liability Litigation, MDL Docket No. 1355, No. 00-md-1355, E.D. La.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 13 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 14%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Supreme Court Justices Question Merck's Defense Of Vioxx Derivative Claims</title>
<description>
<![CDATA[WASHINGTON, D.C. - A U.S. Supreme Court justice pointed out an internal contradiction in Merck &amp; Co.'s defense of a shareholder derivative lawsuit over its marketing of Vioxx during oral argument Nov. 30 - that on the one hand the company argues that it did nothing wrong; on the other, it says shareholders should have been aware much earlier of the possibility that it was covering up the painkiller's cardiovascular risks (Merck &amp; Co., Inc., et al. v. Richard Reynolds, et al., No. 08-905, U.S. Sup.; See November 2009, Page 4). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 14 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 15%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>1st Circuit Say Cy Pres Fund, Rule 23 Properly Used In Zoladex Class Settlement</title>
<description>
<![CDATA[BOSTON - In what it says are two issues of first impression, a unanimous First Circuit U.S. Court of Appeals on Nov. 19 found that the creation of a cy pres charitable fund and application of Federal Rule of Civil Procedure 23(c)(1)(B) were properly applied in a $24 million drug-pricing class settlement (In Re: Pharmaceutical Industry Average Wholesale Price Litigation, M. Joyce Howe v. Leroy Townsend, No. 09-1196, 1st Cir.; 2009 U.S. App. LEXIS 25536). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 15 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 16%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>9th Circuit: Settlement Is No Bar To Defendant's Action Against Third Party</title>
<description>
<![CDATA[SAN FRANCISCO - The False Claims Act (FCA) does not preclude a settling defendant that has made no admission of wrongdoing from seeking recovery from a third party, the Ninth Circuit U.S. Court of Appeals ruled Nov. 18, reversing dismissal of a case stemming from the illegal off-label marketing of a cancer drug (Cell Therapeutics Inc. v. Lash Group Inc., No. 08-35619, 9th Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 16 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 17%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Medtronic Defendants Say False Claims Allegations Are Rehash Of Prior Suits</title>
<description>
<![CDATA[BOSTON - Allegations of illegal kickbacks to induce surgeons to use Medtronic spinal products are a "rehash" of information that has long been public, including in an earlier lawsuit by the same purported relator, defendants/appellees argue in a Nov. 17 brief in the First Circuit U.S. Court of Appeals (United States ex rel. Jacqueline Kay Poteet, et al. v. Lawrence G. Lenke, M.D., et al., No. 09-1728, 1st Cir.; See 11/2/2009, Page 29). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 17 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-23 Mealeys Emerg. Drugs Devices 18%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Lyrica</title>
<description>
<![CDATA[Drug/Device: Lyrica brand pregabalin Defendant(s): Pfizer Inc.; Warner-Lambert Co. LLC Case name: Cynthia L. Hetrick, et al. v. Pfizer Inc., et al., No. 09-9613 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-23 Mealey's Emerg. Drugs Devices 18 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>8th Circuit Upholds Woman's Prempro Verdict, Orders New Punitive Damages Trial</title>
<description>
<![CDATA[ST. LOUIS - The Eighth Circuit U.S. Court of Appeals on Nov. 2 affirmed a jury's $2.75 million compensatory damages award to a woman who claims that her use of Premarin, Prempro and Provera caused her to develop breast cancer and ordered a new trial on her punitive damages claim against Wyeth (Donna Scroggin v. Wyeth, et al., Nos. 08-2555, 08-2711, 08-2713, 8th Cir.; See 3/19/09, Page 10). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$12.8M N.J. Accutane Verdict Cut By $450,000; Most Roche Defense Motions Denied</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - A New Jersey judge on Oct. 28 ordered a $450,000 reduction in a pain and suffering award for an Accutane inflammatory bowel disease (IBD) plaintiff but denied motions for judgment as a matter of law or a new trial in her case and two other cases (In Re: Accutane Litigation, No. 271 MT, Kelly Mace v. Hoffman-La Roche Inc., No. ATL-L-199-05 MT, Lance Sager v. Hoffman-La Roche Inc., No. ATL-L-197-05 MT, Jordan Speisman v. Hoffman-La Roche Inc., No. ATL-L-196-05 MT, N.J. Super., Atlantic Co.; See 11/2/09, Page 11). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>5 Accutane MDL Cases Dismissed For No Causation Expert; 'New Evidence' Denied</title>
<description>
<![CDATA[TAMPA, Fla. - The judge overseeing the Accutane multidistrict litigation on Oct. 28 granted summary judgment in five cases for lack of expert testimony on causation (In Re: Accutane Products Liability, MDL Docket No. 1626, No. 04-md-2523, M.D. Fla., Tampa Div.; 2009 U.S. Dist. LEXIS 103576; See 11/2/09, Page 10). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Calif. Refund Class Certified For AMO Contact Solution</title>
<description>
<![CDATA[SANTA ANNA, Calif. - A California state court judge on Nov. 10 certified a refund class for consumers who purchased the recalled Complete Moisture Plus contact lens solution (In Re: Complete Cases, No. JCCP 4521, Michael Connolly, et al. v. Advanced Medical Optics, Inc., et al., No. 07CC1296, Calif. Super., Orange Co.; See 6/7/07, Page 21). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Panacryl Suture Class Cert Denied By MDL Judge Because Of Competing State Laws</title>
<description>
<![CDATA[RALEIGH, N.C. - The judge presiding over the Panacryl multidistrict litigation on Nov. 13 denied class certification of personal injury claims in part because of the difficulty in applying competing state laws and an unworkable trial plan (In Re: Panacryl Sutures Products Liability Litigation, MDL Docket No. 1959, No. 08-MDL-01958, Alyssa Johnson et al. v. Johnson &amp; Johnson, et al., No. 08-930, Denise Rondot, et al. v. Johnson &amp; Johnson, et al., No. 08-931, Maureen Thompson, et al. v. Johnson &amp; Johnson, et al., No. 08-932, Sandra Vermilyea, et al. v. Johnson &amp; Johnson, et al., No. 08-933, Brian K. Edwards, et al. v. Johnson &amp; Johnson, et al., No. 08-3337, E.D. N.C., Western Div.; See 1/22/09, Page 18). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Ky. Jury Finds GSK Misled About Drug Prices, But Awards State Only $661,860</title>
<description>
<![CDATA[FRANKFORT, Ky. - A Kentucky state court jury on Nov. 13 found that GlaxoSmithKline plc (GSK) violated the state Consumer Protection Act by submitting misleading drug pricing information and awarded the state $661,860 in damages (Commonwealth of Kentucky, ex rel. Jack Conway v. SmithKline Beecham Corporation, et al., No. 04-CI-01487, Ky. Cir., Franklin Co., Div. I). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Brand-Name Drug Makers Owe No Duty To Warn In W. Va. Generics Case</title>
<description>
<![CDATA[CHARLESTON, W.Va. - A West Virginia federal judge on Nov. 13 granted summary judgment for Wyeth and Schwarz Pharma Inc. in a Reglan/metoclopramide injury case after finding that under state case law, neither brand-name drug maker was liable for injuries caused by generic versions of their drug (Shirlean Meade, et al. v. Deidre E. Parsley, D.O., et al., No. 09-388, S.D. W.Va., Charleston Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Supreme Court Invites United States To Opine On Trovan Certiorari</title>
<description>
<![CDATA[WASHINGTON, D.C. - The U.S. Supreme Court invited the U.S. solicitor general on Nov. 2 to express the view of the federal government on whether certiorari should be granted to an appeal involving the claims of Nigerians resulting from a 1996 Trovan clinical trial in Africa, according to the court's online docket (Pfizer, Inc., v. Rabi Abdullahi, et al., No. 09-34, U.S. Sup.; See 9/3/09, Page 22). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Federal Seroquel Investigation Tentatively Settled For $520M, AstraZeneca Reports</title>
<description>
<![CDATA[LONDON - AstraZeneca plc on Oct. 29 said it has reached an agreement in principle with a federal prosecutor to settle an investigation into sales and marketing practices for Seroquel for $520 million. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Eli Lilly Settles Off-Label Zyprexa Claims With Utah For $24 Million</title>
<description>
<![CDATA[SALT LAKE CITY - The Utah Attorney General's office on Nov. 11 announced that Eli Lilly &amp; Co. agreed to pay $24 million to the state to settle claims that the company promoted Zyprexa for off-label uses and that the drug maker concealed its knowledge of the antipsychotic's association with weight gain and obesity. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 11%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$112M Resolves Claims Of Nursing Home Kickbacks To Use J&amp;J's Risperdal</title>
<description>
<![CDATA[WASHINGTON, D.C. - The federal government reached settlements totaling $112 million with a nursing home pharmacy and a drug manufacturer to resolve allegations that they engaged in kickback schemes to promote the use of antipsychotic drugs in nursing home residents, according to a Nov. 3 press release (United States of America ex rel. Adam B. Resnick, et al. v. Omnicare Inc., et al., No. 06-10149, United States of America ex rel. David M. Kammerer, et al. v. Omnicare Inc., et al., No. 05-11519, D. Mass.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 11 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 12%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Boston Scientific To Pay $296M To Resolve Probe Into Defective Defibrillators</title>
<description>
<![CDATA[NATICK, Mass. - Boston Scientific Corp. announced Nov. 6 that it has reached a $296 million settlement in principle with the U.S. Department of Justice stemming from allegations that its Guidant subsidiary failed to notify the U.S. Food and Drug Administration about problems with some of its implantable cardiac defibrillators in 2005 (See 5/21/2009, Page 14). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 12 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 13%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>3rd-Party Payers' Antitrust, Consumer Protection Claims Over Wellbutrin Dismissed</title>
<description>
<![CDATA[PHILADELPHIA - Antitrust and consumer protection claims brought by a proposed class of end-payers alleging that GlaxoSmithKline engaged in a fraudulent scheme to extend patent protection over Wellbutrin, thus requiring the plaintiffs to pay more for the antidepressant than a generic, were dismissed by a Pennsylvania federal judge on Nov. 3 after he found that the plaintiffs' lacked standing to bring the claims (Sheet Metal Workers Local 441, et al. v. GlaxoSmithKline PLC, et al., No 04-5898, E.D. Pa.; 2009 U.S. Dist. LEXIS 102087). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 13 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 14%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Prozac Plaintiff Denied Expert Witness 'Do-Over'</title>
<description>
<![CDATA[ALBUQUERQUE, N.M. - A New Mexico federal judge on Nov. 16 denied a plaintiff's request to designate a new causation expert in a Prozac wrongful death case, saying it came too late (Mark Gilbert Rimbert, et al. v. Eli Lilly and Company, No. 06-874, D. N.M.; See 8/6/09, Page 20). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 14 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 15%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Forest Labs Settlement Falls Within $170M Reserve, Company Reports</title>
<description>
<![CDATA[NEW YORK - Forest Laboratories Inc. has tentatively settled lawsuits filed by the U.S. government concerning alleged improper marketing of the antidepressants Celexa and Lexapro and the thyroid medication Levothroid, and the amount of the agreements falls within the $170 million the company has reserved for such matters, according to a Form 10-Q the drug maker submitted Nov. 9 with the U.S. Securities and Exchange Commission. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 15 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 16%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Maker Of Generic Paxil Again Seeks Preemption For Wrongful Death Claims</title>
<description>
<![CDATA[PHILADELPHIA - Saying the regulatory background matches the exception carved out of a landmark Supreme Court ruling against federal preemption of state pharmaceutical claims, the manufacturer of a generic version of the antidepressant Paxil on Nov. 9 for a second time moved for summary judgment based on federal conflict preemption (Joseph C. Colacicco, et al. v. Apotex, Inc., et al., No. 05-5500, E.D. Pa.; See 9/3/2009, Page 20). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 16 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 17%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Study Says Moms' Use Of Antidepressants Linked To Children's Health Risks</title>
<description>
<![CDATA[OXFORD, England - A study published Nov. 3 in the British Journal of Obstetrics and Gynecology revealed that children who were exposed to antidepressants while the mother was pregnant have higher risks of certain health problems compared to other children their age. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 17 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 18%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Judge: UCL Claims Against InterMune For Allegedly Overhyping Off-Label Use Fail</title>
<description>
<![CDATA[SAN FRANCISCO - Plaintiffs have not shown how allegedly false statements about a drug's efficacy in off-label usage caused them to purchase the product, a California federal judge held Nov. 6 in dismissing unfair competition law (UCL) claims (In re: Actimmune Marketing Litigation, No. 08-2376, N.D. Calif.; 2009 U.S. Dist. LEXIS 103408; See 7/23/09, Page 24). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 18 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 19%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Sleep-Driving Experts Insufficient To Support Drug Maker's Negligence</title>
<description>
<![CDATA[LOUISVILLE, Ky. - Review of a small number of case reports linking the sleep aid Ambien to sleep driving is insufficient foundation for two expert opinions that a woman was sleep driving when she crashed her car into a utility pole, a federal judge in Kentucky held Oct. 29 in excluding the experts (Darlene Gibson v. sanofi-aventis U.S., No. 3:07CV-192-S, W.D. Ky.; 2009 U.S. Dist. LEXIS 102864). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 19 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 20%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Avandia Plaintiffs Say Glaxo Is Stonewalling Document Production</title>
<description>
<![CDATA[PHILADELPHIA - The Plaintiffs' Steering Committee (PSC) in consolidated litigation over the diabetes drug Avandia says in a Nov. 10 motion filed in the U.S. District Court for the Eastern District of Pennsylvania that with the first trials less than seven months away, manufacturer GlaxoSmithKline plc (GSK) is holding up discovery with an invocation of privilege so sweeping as to "raise due process issues" (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL Docket No. 1871, No. 07-md-1871, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 20 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 21%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>FDA Warns Of Kidney Problems With Diabetes Drug</title>
<description>
<![CDATA[ROCKVILLE, Md. - The U.S. Food and Drug Administration has warned physicians and diabetics using Amylin Pharmaceuticals' Byetta (exenatide) to be on the watch for symptoms of kidney function problems, including kidney failure. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 21 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 22%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Arkansas Supreme Court Affirms Dismissal Of Nexium Consumer Claims</title>
<description>
<![CDATA[LITTLE ROCK, Ark. - The Arkansas Supreme Court on Nov. 5 affirmed a lower court's finding that plaintiffs asserting consumer claims over AstraZeneca's promotion of its heartburn medication Nexium as superior to its cheaper Prilosec failed to state a cause of action (Louise DePriest, et al. v. AstraZeneca Pharmaceuticals L.P., No. 08-1257, Ark. Sup.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 22 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 23%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Federal Suit Alleges Amgen Offered Doctors Kickbacks To Prescribe Anemia Drug</title>
<description>
<![CDATA[BOSTON - Alleging illegal kickbacks to promote sales of its anemia drug Aranesp, 14 states and the District of Columbia joined a false claims lawsuit against Amgen Inc. on Oct. 30 in federal court (The United States of America ex rel. Kassie Westmoreland, et al. v. Amgen Inc., et al., No. 06-10972, D. Mass.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 23 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 24%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>AtriCure Announces $3.8M Settlement Over Surgical Ablation Claims</title>
<description>
<![CDATA[WEST CHESTER, Ohio - AtriCure Inc., a medical device company, announced Nov. 4 that it had reached a tentative agreement with the Department of Justice (DoJ) to resolve claims that it defrauded Medicare by promoting microwave surgical ablation devices off label to correct atrial fibrillation (United States of America, ex rel. Jane Doe v. Atricure Inc., No. 07-2702, S.D. Texas; See 7/23/09, Page 30). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 24 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 25%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Whistle-Blower Suit Alleges Pharmaceutical Bribery And Kickbacks</title>
<description>
<![CDATA[PHILADELPHIA - In the first complaint to be filed since a False Claims Act lawsuit was unsealed in federal court in August, a 13-year employee of benefits manager Medco Health Solutions Inc. alleges in an Oct. 26 complaint widespread fraud, bribery and kickbacks involving several drugs Medco distributed (United States of America ex rel. Karl S. Schumann, et al. v. AstraZeneca Pharmaceuticals, et al., No. 03-5423, E.D. Pa.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 25 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 26%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Ohio Class Actions Assert Consumer Claims Over Misbranded Cold Products</title>
<description>
<![CDATA[COLUMBUS, Ohio - In the wake of a warning from the U.S. Food and Drug Administration that the addition of vitamin C to Procter &amp; Gamble Co.'s (P&amp;G) cold products DayQuil and NyQuil makes them misbranded, two putative consumer class actions were filed Nov. 4 in the U.S. District Court for the Southern District of Ohio (Richard Loreto et al. v. The Proctor &amp; Gamble Company, No. 1:09CV815, Stephen Inocencio et al. v. The Proctor &amp; Gamble Company, No. 1:09CV813, S.D. Ohio, Western Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 26 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 27%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>9th Circuit Reverses Dismissal Of Zicam Securities Fraud Class Action</title>
<description>
<![CDATA[SAN FRANCISCO - A district court erroneously relied on the statistical significance standard in concluding that a class of investors, who were alleging that a pharmaceutical company committed securities fraud by failing to disclose a side effect of its cold remedy drug, failed to establish materiality, a panel of the Ninth Circuit U.S. Court of Appeals ruled Oct. 28, reversing and remanding dismissal of the class (James Siracusano, et al. v. Matrixx Initiatives, Inc., et al., No. 06-15677, 9th Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 27 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 28%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Stryker Biotech, 4 Execs Indicted For Off-Label Sales Of Bone Repair Products</title>
<description>
<![CDATA[BOSTON - Stryker Biotech LLC and four current or former executives were indicted Oct. 28 on federal criminal charges of conspiracy, making false statements, wire fraud and misbranding in connection with off-label promotion of two of its bone repair products (United States of America v. Stryker Biotech, LLC, et al., No. n/a, D. Mass.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 28 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 29%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>New FDA Program Targets Preventable Harm From Drugs</title>
<description>
<![CDATA[SILVER SPRING, Md. - The U.S. Food and Drug Administration announced the Safe Use Initiative on Nov. 4, aimed at reducing the likelihood of preventable harm from medication use. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 29 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 30%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Liver Damage Victim Wins $4M Ruling Against Manufacturer's Insurer</title>
<description>
<![CDATA[MIAMI - A woman who required a liver transplant after using the energy supplement Up Your Gas won a $4 million declaration on Nov. 9 in a Florida federal court that the policy James River Insurance Co. issued to the manufacturer does not contain a policy date based on occurrence but based on claims made (James River Insurance Company v. Laura Dimauro, et al., No. 08-23235, S.D. Fla., Miami Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 30 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 31%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>FDA: Don't Use 'Shoulder Pain Pumps' Because Of Adverse Events</title>
<description>
<![CDATA[ROCKVILLE, Md. - The Food and Drug Administration on Nov. 13 said local anesthetics and drug pumps are not approved for use in treating post-surgical shoulder pain. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 31 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 32%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Synthes Spinal Disc Device Recalled After Component Fails</title>
<description>
<![CDATA[ROCKVILLE, Md. - Synthes Ti Synex II Vertebral Body Replacement spinal devices have been recalled after the central body component failed, the Food and Drug Administration announced Nov. 12. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 32 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 33%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Wound Therapy System Tied To Deaths, Injuries</title>
<description>
<![CDATA[ROCKVILLE, Md. - The Food and Drug Administration on Nov. 16 issued a preliminary public health notification of six deaths and 77 injuries associated with the Negative Pressure Wound Therapy systems. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 33 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-22 Mealeys Emerg. Drugs Devices 34%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Outcomes In Studies Of Off-Label Neurontin Use Were Altered, Journal Says</title>
<description>
<![CDATA[BOSTON - Published research into off-label uses for the epilepsy drug Neurontin is inconsistent with the results shown in internal Pfizer documents, according to a study published Nov. 12 in the New England Journal of Medicine. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-22 Mealey's Emerg. Drugs Devices 34 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 1%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Mont. Jury Awards $3.2M In 1st Zometa Jaw Injury Case To Go To Verdict</title>
<description>
<![CDATA[MISSOULA, Mont. - In the first bisphosphonate case to go to verdict, a Montana state court jury on Oct. 21 awarded a plaintiff $3.2 million after finding that Novartis Pharmaceuticals Corp. was negligent in failing to warn her doctors of the risks of its Zometa bone-loss prevention drug and causing her osteonecrosis of the jaw (ONJ) (Peggy L. Stevens v. Novartis Pharmaceuticals Corporation, No. DV-08-100, Mont. Dist., 4th Dist., Missoula Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 1 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 2%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>British Citizen's Fosamax Case Dismissed From MDL Court On Forum Non Conveniens</title>
<description>
<![CDATA[NEW YORK - The judge overseeing the Fosamax multidistrict litigation on Oct. 21 granted Merck &amp; Co. Inc.'s motion to dismiss a British plaintiff's complaint on the basis of forum non conveniens provided that Merck agrees to be sued in a British court, to waive any statute of limitations defense and to make necessary witnesses available (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 06-md-1789, Barbara Anne Miller v. Merck &amp; Co. Inc., No. 06-5087, S.D. N.Y.; 2009 U.S. Dist. LEXIS 110831). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 2 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 3%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$7M Fla. Accutane Verdict Reversed By Appeals Court On Learned Intermediary</title>
<description>
<![CDATA[TALLAHASSEE, Fla. - A Florida appeals court panel on Oct. 27 reversed a $7 million Accutane inflammatory bowel disease (IBD) verdict, finding that the plaintiff had not proven failure to warn and causation and that his claim was barred by the learned intermediary doctrine (Hoffman-La Roche Inc., et al. v. Adam W. Mason, No. 1D08-2023, Fla. App., 1st Dist.; 2009 Fla. App. LEXIS 15997; See 10/18/07, Page 6). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 3 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 4%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Roche Wants Fla. Ruling Applied Post-Verdict To N.J. Accutane Cases</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - Accutane defendant Hoffman-La Roche Inc. lost no time in telling New Jersey's Accutane judge that she should apply an Oct. 27 Florida appeals court ruling to three New Jersey cases that resulted in a $12.9 million verdict (In Re: Accutane Litigation, No. 271 MT, Kelly Mace v. Hoffman-La Roche Inc., No. ATL-L-199-05 MT, Lance Sager v. Hoffman-La Roche Inc., No. ATL-L-197-05 MT, Jordan Speisman v. Hoffman-La Roche Inc., No. ATL-L-196-05 MT, N.J. Super., Atlantic Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 4 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 5%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Accutane MDL Plaintiffs Want New Evidence, Consultant Role Reconsidered By Court</title>
<description>
<![CDATA[TAMPA, Fla. - Plaintiffs in the Accutane multidistrict litigation on Oct. 13 asked the court to consider new evidence that it says supports the theory of an expert the court recently rejected (In Re: Accutane Products Liability, MDL Docket No. 1626, No. 04-md-2523, M.D. Fla., Tampa Div.; See 8/20/09, Page 14). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 5 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 6%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Roche: Poster Abstract Is Unreliable Evidence In Accutane Post-Trial Motion</title>
<description>
<![CDATA[ATLANTIC CITY, N.J. - An abstract presented as a poster at a medical conference should be considered hearsay and not scientific evidence, Hoffman-La Roche Inc. told the New Jersey Accutane court on Oct. 16 (In Re: Accutane Litigation, No. 271 MT, Kelly Mace v. Hoffman-La Roche Inc., No. ATL-L-199-05 MT, Lance Sager v. Hoffman-La Roche Inc., No. ATL-L-197-05 MT, Jordan Speisman v. Hoffman-La Roche Inc., No. ATL-L-196-05 MT, N.J. Super., Atlantic Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 6 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 7%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Jury Awards Punitive Damages In Pa. Prempro Case, But Judge Seals Amount</title>
<description>
<![CDATA[PHILADELPHIA - A Pennsylvania state court jury on Oct. 26 ordered Prempro maker Wyeth Inc. to pay punitive damages to an Illinois woman who claims that her use of the hormone replacement therapy caused her to develop breast cancer, but the judge presiding over hormone replacement therapy mass tort proceedings ordered the amount sealed until the conclusion of a similar case in the same court (Connie Barton v. Wyeth Pharmaceuticals Inc., Case No. 040406301, Pa. Comm. Pls., Philadelphia Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 7 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 8%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Fla. Federal Judge: Levine Applies Fully To Generic Drug Makers</title>
<description>
<![CDATA[TALLAHASSEE, Fla. - A Florida federal judge on Oct. 15 denied a motion for summary judgment in a generic Adderall case, finding that a U.S. Supreme Court ruling allowing brand-name drug makers to strengthen drug warning labels fully applies to generic manufacturers (Jane R. Munroe, et al. v. Barr Laboratories, Inc., No. 07-395, N.D. Fla., Tallahassee Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 8 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 9%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>South Carolina Zyprexa Case Settles For $45M, Restrictions On Off-Label Marketing</title>
<description>
<![CDATA[SPARTANBURG, S.C. - Eli Lilly and Co. settled South Carolina's state court Zyprexa off-label lawsuit for $45 million, state Attorney General Henry McMaster announced Oct. 23 (State of South Carolina, ex rel. Henry McMaster v. Eli Lilly and Company, No. 2007-CP-42-1855, S.C. Comm. Pls., 7th Jud. Cir.; See 10/15/09, Page 18). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 9 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 10%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>10th Circuit Affirms Penalty Against TMJ Maker For Not Reporting Adverse Events</title>
<description>
<![CDATA[DENVER - A panel of the 10th Circuit U.S. Court of Appeals on Oct. 27 affirmed a $170,000 penalty against the maker of temporomandibular joint (TMJ) implants and its president for knowingly failing to report adverse events to the Food and Drug Administration (TMJ Implants, Inc., et al. v. United States Department of Health and Human Services, No. 08-9539, 10th Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 10 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 11%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>NuvaRing MDL Judge Strikes Filing Of Master Complaint</title>
<description>
<![CDATA[ST. LOUIS - The federal judge presiding over the NuvaRing products liability multidistrict litigation on Oct. 23 decided to strike the master complaint from the docket because he did not expect the manufacturers of the contraceptive to seek dismissal of the complaint under Federal Rule of Civil Procedure 12(b) or appeal his ruling denying the motion (In re: NuvaRing Products Liability Litigation, MDL No. 1964, Case No. 08-md-1964, E.D. Mo.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 11 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 12%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$110 Million Settlement In Toxic Vitamin Solution Class Preliminarily Approved</title>
<description>
<![CDATA[WICHITA FALLS, Texas - A federal judge in Texas on Oct. 10 preliminarily approved a $110 million settlement involving claims that a vitamin solution for infants was unreasonably dangerous (Victoria Klein, et al. v. O'Neal Inc., et al. v. Federal Insurance Co., et al., No. 7:03-cv-102, N.D. Texas). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 12 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 13%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Medtronic Sprint Fidelis State Court Litigation Ruled Preempted Under Riegel</title>
<description>
<![CDATA[MINNEAPOLIS - A Minnesota state court judge held Oct. 20 that the claims of nine representative plaintiffs in that state's consolidated Medtronic Inc. Sprint Fidelis implantable defibrillator leads litigation are preempted by federal law (In Re: Medtronic Sprint Fidelis Lead Products State Court Litigation, No. 27-CV-07-22446, Minn. Dist., Hennepin Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 13 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 14%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>7th Circuit: No Error In District Court Dismissal Of Guidant Securities Class</title>
<description>
<![CDATA[CHICAGO - A district court did not err in dismissing without prejudice a putative investor class alleging that Guidant Corp. misrepresented the safety of its Ventak implantable cardioverter defibrillator (ICD) products and a pending merger with Johnson &amp; Johnson (J&amp;J), a Seventh Circuit U.S. Court of Appeals panel ruled Oct. 21 (David Fannon, et al. v. Guidant Corp., et al., No. 08-2429, 7th Cir.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 14 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 15%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Fraud-On-FDA Not Prerequisite To N.J. Punitive Damage Claim In Elidel Cancer Case</title>
<description>
<![CDATA[CAMDEN, N.J. - Proof of fraud on the Food and Drug Administration in an Elidel cancer case is only a prerequisite to a New Jersey state law punitive damage claim, a federal judge ruled Oct. 19 in remanding the case (Roderick Devine v. Novartis Pharmaceuticals Corporation, et al., No. 08-859, D. N.J.; 2009 U.S. Dist. LEXIS 97555). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 15 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 16%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Pain Pump Preemption Appeal Dismissed When Plaintiff Fails To File Record Excerpts</title>
<description>
<![CDATA[ATLANTA - The 11th Circuit U.S. Court of Appeals on Oct. 21 dismissed a pain pump preemption case for want of prosecution after the plaintiff missed a deadline for filing record excerpts (Linda Wolicki-Gables v. Arrow International, Inc., No. 09-14342, 11th Cir.; See 8/6/09, Page 18). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 16 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 17%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>AstraZeneca Dismissed From Shoulder Pump Case For Failure To Adequately Plead</title>
<description>
<![CDATA[PHOENIX - An Arizona federal judge on Oct. 15 dismissed without prejudice claims against drug manufacturer AstraZeneca Pharmaceuticals LP in a shoulder pain pump case after finding that the plaintiff failed to satisfy pleading requirements (Andrew Gilmore, et al. v. DJO Incorporated, et al., No. 08-1252, D. Ariz.; 2009 U.S. Dist. LEXIS 96690). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 17 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 18%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Summary Judgment Granted After Implant Patient Fails To Show Parallel Claims</title>
<description>
<![CDATA[PHOENIX - A breast implant plaintiff failed to show that her state law tort claims paralleled federal requirements and are thus preempted, an Arizona federal judge said Oct. 14 in granting summary judgment to defendant Allergan USA Inc. (Karen Williams, et al. v. Allergan USA, Inc., et al., No. 09-1160, D. Ariz.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 18 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 19%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Paxil Defect Plaintiff Allowed To Supplement Expert Causation Report</title>
<description>
<![CDATA[TULSA, Okla. - A plaintiff in a Paxil birth defect case can submit a supplemental expert report that expands on her original causation opinion, an Oklahoma federal judge ruled Oct. 26 (Jennifer Hayes, et al. v. SmithKline Beecham Corporation, et al., No. 07-682, N.D. Okla., Tulsa Div.; 2009 U.S. Dist. LEXIS 98499). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 19 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 20%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>W. Va. Public Policy Stops Learned Intermediary In Fentanyl Patch Case</title>
<description>
<![CDATA[CHARLESTON, W.Va. - Mylan Inc. on Oct. 23 asked a West Virginia federal court to reconsider its Oct. 14 order denying dismissal of a fentanyl patch death case on choice of law (Lynn Woodcock, et al. v. Mylan, Inc., et al., No. 09-507, S.D. W.Va., Charleston Div.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 20 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 21%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Colonoscopy Snare Complaint Remanded On Assurance About Limited Recovery</title>
<description>
<![CDATA[LOUISVILLE, Ky. - A Kentucky federal judge on Oct. 23 remanded a medical device case to state court based on the plaintiff's lawyers' affirmation that he is not seeking an amount in excess of the federal threshold amount of $75,000 (Richard B. Van Etten v. Boston Scientific Corporation, No. 09-442, W.D. Ky., Louisville Div.; 2009 U.S. Dist. LEXIS 99079). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 21 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 22%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Indocin SJS Case Out For Lack Of Experts</title>
<description>
<![CDATA[MEMPHIS, Tenn. - A case in which a plaintiff alleged that he developed Stevens-Johnson syndrome (SJS) from Merck &amp; Co. Inc.'s Indocin rheumatoid arthritis drug was dismissed on summary judgment on Oct. 16 because the plaintiff failed to identify expert witnesses (John Taylor v. Merck &amp; Co. Inc., No. 08-2244, W.D. Tenn., W. Div.; 2009 U.S. Dist. LEXIS 96696). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 22 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 23%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Preemption Gone, Zeneca Argues Pleading Defects In Nexium / Prilosec Suit</title>
<description>
<![CDATA[WILMINGTON, Del. - With its preemption summary judgment taken away, Zeneca Inc. on Sept. 15 asked a Delaware federal judge to dismiss a Nexium/Prilosec economic injury case on failure to plead with specificity (Pennsylvania Employee Benefit Trust Fund, et al. v. Zeneca, Inc., et al., No. 05-75, D. Del.; See 3/19/09, Page 7). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 23 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 24%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$1.2M Rezulin Fee Agreement Affirmed By N.Y. Appeals Court</title>
<description>
<![CDATA[NEW YORK - A New York state appeals court on Oct. 22 unanimously affirmed a $1,261,521 fee-sharing judgment in the state's Rezulin mass tort litigation (In Re: New York Rezulin Products Liability Litigation, William Andrews, et al. v. Pfizer, Inc., Girardi &amp; Keese v. Duffy, Duffy &amp; Burdo, Esq., Nos. 1250, 752000/00, 104463/04, N.Y. Sup. App., 1st Dept.; 2009 N.Y. App. Div. LEXIS 7342). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 24 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 25%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Whistle-Blowers: Judge Set 'Public Disclosure' Bar To Be Overly Broad</title>
<description>
<![CDATA[BOSTON - The federal judge who dismissed allegations that doctors accepted kickbacks from Medtronic Sofamor Danek USA Inc. (MSD) in return for off-label promotion of its bone growth product used a standard for previous "public disclosure" pursuant to the False Claims Act (FCA) so broad as to invite drug companies to inoculate themselves by filing bogus lawsuits, appellees argue in a brief filed Oct. 14 in the First Circuit U.S. Court of Appeals (United States ex rel. Jacqueline Kay Poteet, et al. v. Lawrence G. Lenke, M.D., et al., No. 09-1728, 1st Cir; See 4/2/09, Page 21). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 25 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 26%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Zicam Makers Say FDA Won't Change Position That Sprays Are Injurious Drugs</title>
<description>
<![CDATA[SCOTTSDALE, Ariz. - Zicam maker Matrixx Initiatives Inc. said Oct. 26 that the Food and Drug Administration is unwilling to reverse its position that the company's zinc-based nasal sprays are unapproved new drugs that are linked to patients losing their sense of smell and/or taste. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 26 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 27%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>United States Sides With Merck Investors In Supreme Court</title>
<description>
<![CDATA[WASHINGTON, D.C. - The U.S. Office of the Solicitor General filed an amicus curiae brief in Vioxx derivative litigation on Oct. 26 before the U.S. Supreme Court, supporting a putative class of Vioxx derivative plaintiffs who say that even if they were on "inquiry notice" of potential securities fraud in September 2001, they could not have established the requisite scienter until learning that that Merck &amp; Co. Inc. executives did not believe their own claims of the drug's safety (Merck &amp; Co., Inc., et al. v. Richard Reynolds, et al., No. 08-905, U.S. Sup.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 27 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 28%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>$274M Pricing Verdicts Against 3 Major Drug Companies Vacated By Ala. High Court</title>
<description>
<![CDATA[MONTGOMERY, Ala. - The Alabama Supreme Court on Oct. 16 vacated $274 million in two prescription drug average wholesale price verdicts and entered judgment in favor of AstraZeneca LP, Novartis Pharmaceuticals Corp. and GlaxoSmithKline plc (GSK), finding that they did not defraud the state Medicaid program and cause it to pay higher-than-needed reimbursement to health care providers (AstraZeneca LP, et al. v. State of Alabama, Nos. 1071439 and 1071704, SmithKline Beecham Corporation, et al. v. State of Alabama, No. 1071704, and Novartis Pharmaceuticals Corporation v. Alabama, No. 1071759, Ala. Cir., Montgomery Co.; See 3/6/08, Page 26). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 28 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 29%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Kentucky Jury Hits AstraZeneca For $14.7M In Drug Overpricing Suit</title>
<description>
<![CDATA[FRANKFORT, Ky. - A Kentucky Circuit Court jury entered a $14.7 million verdict on Oct. 15 against AstraZeneca for defrauding the Kentucky Medicaid program and state consumers by inflating the average wholesale prices (AWPs) of the company's prescription drugs (Commonwealth of Kentucky v. Alpharma Inc., 2004-ci-1487, Ky. Cir., Franklin Co.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 29 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 30%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>3 Drug Makers Settle False Claims Lawsuit For $124M</title>
<description>
<![CDATA[WASHINGTON, D.C. - Three drug companies will pay a total of $124 million to settle False Claims Act allegations that they or their subsidiaries underpaid rebates due to the federal government for drugs sold to the Medicaid program, the U.S. justice announced Oct. 20 (Citizens For Consumer Justice, et al. v. Abbott Laboratories, et al., No. 01-12257, D. Mass.; See 9/13/09, Page 32). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 30 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 31%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Court: Baycol User Entitled To Amend UCL Action To Show He Paid Higher Prices</title>
<description>
<![CDATA[LOS ANGELES - A judge erred in denying a man leave to amend his unfair competition law action to specify how he paid higher prices as a result of a drug company's overstating of the benefits and safety of its cholesterol-lowering drug, a California appeals court held Oct. 20 (In re Baycol Cases I and II, No. B204943, Calif. App., 2nd Dist.). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 31 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 32%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Objectors To Class Settlement Appeal $70M Fee Award In Drug-Pricing Case</title>
<description>
<![CDATA[BOSTON - After a federal Massachusetts judge approved $70 million in attorney fees following a $350 million settlement in a class action fraudulent drug-pricing case, class members opposing the settlement filed notices of appeal (New England Carpenters Health Benefits Fund, et al. v. First Databank Inc., et al., No. 05-11148, D. Mass.; 2009 U.S. Dist. LEXIS 68419; See 9/3/09, Page 29). 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 32 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>
 
<item>
<link>http://www.mealeysonline.com/mealey/ppv/articleSearch.do?searchTerm=%22%2014-21 Mealeys Emerg. Drugs Devices 33%20(2009)%20%22&amp;pageLimit=10&amp;pageNumber=0&amp;publication=All+Mealey+Publications%3BMEALEY%3BMEALEY&amp;relativeDateValue=NONE&amp;fromDate=&amp;toDate=&amp;loc=mealeysrss</link>
<title>Philips Healthcare Voluntarily Recalls Defibrillators For Memory Chip Failure</title>
<description>
<![CDATA[SEATTLE - Philips Healthcare announced Sept. 28 that it is voluntarily recalling 5,400 HeartStart FR2+ automated external defibrillators (AEDs) due to the possibility of a memory chip failure that could render the device inoperable. 
<a href="http://www.lexis.com/research/xlink?canceldest=form&amp;keyenum=25271&amp;keytnum=0&amp;searchtype=get&amp;search=14-21 Mealey's Emerg. Drugs Devices 33 (2009)&amp;view=full&amp;ORIGINATION_CODE=00144" target="_blank">Full story on lexis.com</a>]]>
</description>
</item>

</channel>

</rss> 

